In particular, IL-23/Th17 axis was shown to be central in amplification of inflammation and cutaneous manifestations of psoriasis as supported by the high therapeutic efficacy of anti-IL-17 antibodies used in clinical trials. Here, IL17A is linked to psoriasis.